Clinical development failure
LP-300, LP-184, LP-284 and other programs may not show sufficient efficacy or safety to advance.
- Scope
- Lead pipeline programs
- Materiality
- high
Lantern Pharma Inc.
Lantern Pharma Inc. is a clinical-stage biopharmaceutical company focused on using its RADR® AI/ML platform to discover and develop oncology drug candidates. It combines de novo biomarker-guided programs with a “rescue” strategy for previously studied compounds that may be repurposed for more targeted cancer trials.
2.40
2.40
| % | |
|---|---|
| Clinical-stage oncology programs | 70% Drug candidates in preclinical and clinical development for cancer indications. |
| AI-enabled discovery platform | 20% RADR® and related machine-learning tools used to identify and de-risk candidates. |
| Rescue and repurposing pipeline | 10% Previously studied compounds being re-evaluated with biomarker and AI methods. |
Lantern Pharma does not sell commercial medicines today; its primary “customers” are investors, research partners, and...
- Capital providersprimary
Equity investors and other financiers fund the company because it has no product revenue and needs capital for development.
- Strategic partnerssecondary
Pharma or biotech partners may license, co-develop, or acquire programs to share development risk and access the RADR® platform.
- Grant agenciessecondary
Public or private grant funders may support specific research or translational work to extend runway.
- Future oncology treatment marketemerging
If approved, hospitals, physicians, and patients would use the therapies for biomarker-guided cancer treatment.
Lantern Pharma is headquartered in the United States and reports no product revenue to date...
- •United States is the corporate and financing base
- •Clinical testing activity includes Taiwan for LP-300
- •No disclosed product revenue by country to date
- •Future commercialization could expand beyond the U.S.
- •Geographic execution matters because trials and regulation vary by market
The company’s strategy is to build an oncology pipeline using RADR® and other machine-learning methods, while also...
01
Advance lead oncology candidatesshort-term
Clinical progress is the main value driver because the company currently has no product revenue.
02
Use AI to de-risk developmentmedium-term
RADR® and biomarker-guided selection are intended to improve trial success rates and reduce wasted spend.
03
Secure additional capitalshort-term
The company expects substantial future funding needs to support trials and operations.
Lantern Pharma is a pre-revenue biotech, so its business depends on successful clinical development, regulatory...
Capital dilution and liquidity pressure
The company expects substantial additional funding needs and may need to raise equity on unfavorable terms.
- Scope
- Operating runway and ownership dilution
- Materiality
- high
Commercialization uncertainty
Even if candidates succeed clinically, the company must still build manufacturing, sales, and distribution capabilities.
- Scope
- Future launch readiness
- Materiality
- high
Geopolitical and trial execution risk in Taiwan
Management explicitly cited Taiwan as a location for clinical testing, which can affect timelines and operations.
- Scope
- Clinical operations
- Materiality
- medium
Revenue recognition
Reported revenue may remain minimal until a partnership or approval occurs
Research and development expense timing
Quarterly results may not be directly comparable across periods
Equity financing and dilution
Share count and per-share metrics can change materially
Going-concern style liquidity assessment
Runway and financing assumptions are central to valuation
: 28.4.2026